|本期目录/Table of Contents|

[1]支黎明,姚祎,李文娟综述,等.嵌合抗原受体Ｔ 细胞功能设计与运用的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2017,19(01):70-75.[doi:10.3969/j.issn.1672-271X.2017.01.019]
点击复制

嵌合抗原受体Ｔ 细胞功能设计与运用的研究进展()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第19卷
期数:
2017年01期
页码:
70-75
栏目:
综述
出版日期:
2017-01-20

文章信息/Info

Title:
-
作者:
支黎明; 姚祎; 李文娟综述; 王晶审校
作者单位：210002南京，解放军第454医院转化医学中心
Author(s):
-
关键词:
嵌合抗原受体T细胞; CAR功能设计; CAR-T运用
Keywords:
-
分类号:
R392
DOI:
10.3969/j.issn.1672-271X.2017.01.019
文献标志码:
A
摘要:
嵌合抗原受体T细胞（chimeric antigen receptor engineered T cell, CAR-T）治疗在B细胞恶性肿瘤治疗的临床试验中取得了巨大成功，引起了业界极大的关注。文章就CAR功能区域，CAR功能设计和CAR-T运用等方面研究进展进行综述。
Abstract:
-

参考文献/References:

[1]Oren R, Hod-Marco M, Haus-Cohen M, et al. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds [J]. J Immunol, 2014, 193: 5733-5743.
[2]Tamaskovic R, Simon M, Stefan N, et al.Designed ankyrin repeat proteins (DARPins) from research to therapy [J]. Meth Enzymol, 2012, 503: 101-134.
[3]Procko E, Berguig GY, Shen BW, et al.A computationally designed inhibitor of an Epstein-Barr viral Bcl-2 protein induces apoptosis in infected cells [J]. Cell, 2014, 157: 1644-1656.
[4]Bridgeman JS, Hawkins RE, Bagley S, et al. The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex[J]. J Immunol, 2010, 184: 6938-6949.
[5]Shirasu N, Shibaguci H, Kuroki M, et al. Construction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigen[J]. Anticancer Res, 2010, 30: 2731-2738.
[6]Kochenderfer JN, Dudley ME, Feldman SA, et al.B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells [J]. Blood, 2012, 119: 2709-2720.
[7]Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al.T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial [J]. Lancet, 2014, 385: 517-528.
[8]Zhong XS, Matsushita M, Plotkin J, et al. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication [J]. Mol Ther, 2010, 18: 413-420.
[9]Hogquist KA, Jameson SC. The self-obsession of T cells: how TCR signaling thresholds affect fate“decisions”and effector function[J]. Nat Immunol, 2014, 15: 815-823.
[10]Huang J, Brameshuber M, Zeng X, et al.A single peptide-major histocompatibility complex ligand triggers digital cytokine secretion in CD4+ T cells [J]. Immunity, 2013, 39: 846-857.
[11]Srivastava S, Stanley R. Engineering CAR-T Cells: Design Concepts [J]. Trends Immunol, 2015, 36: 494-502.
[12]Cordoba SP, choudhuri K, Zhang H, et al.The large ectodomains of CD45 and CD148 regulate their segregation from and inhibition of ligated T-cell receptor [J]. Blood, 2013, 121: 4295-4302.
[13]Haso W, Lee DW, Shah NN, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia[J]. Blood, 2013, 121: 1165-1174.
[14]Hudecek M, Sommermeyer D, Kosasih PL, et al.The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity [J]. Cancer Immunol Res, 2015, 3: 125-135.
[15]Stone JD, Chervin AS, Kranz DM. T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity[J]. Immunology, 2009, 126: 165-176.
[16]Oren R, Hod-Marco M, Haus-cohen M, et al. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds[J]. J Immunol, 2014, 193: 5733-5743.
[17]Nauerth M,Weibrich B, Knall R, et al. TCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer [J]. Sci Transl Med, 2013, 5: 192ra87.
[18]Chinnasamy D, Yu Z, Kerkar SP,et al. Local delivery of interleukin.12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice [J]. Clin Cancer Res, 2012, 18: 1672-1683.
[19]Wilkie S, Burbridge SE, Chiapero-Stanke L, et al. Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4[J]. J Biol Chem, 2010, 285: 25538-25544.
[20]Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a“safety switch”to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells[J]. Front Pharmacol, 2014, 5: 235.
[21]Chia-Yung Wu, Roybal KT, Puchner EM, et al. Remote control of therapeutic T cells through a small molecule gated chimeric receptor[J]. Science, 2015, 350: aab4077.
[22]Kloss CC, Condomines M, Cartellieri M, et al.Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells [J]. Nat Biotechnol, 2013, 31: 71-75.
[23]Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses[J]. Sci Transl Med, 2013, 5: 215ra172.
[24]徐成润.PD-1/PD-L1负性协同刺激通路在乙型病毒性肝炎慢性化中的地位及进展[J]. 东南国防医药,2015,17(5):514-516.
[25]伍筱玫,雷月.程序性死亡受体-1/配体-1在卵巢癌中的研究进展[J]. 医学研究生学报,2017,30(1):108-112.
[26]Robert C, Schachter J, Long GV,et al. Pembrolizumab versus ipilimumab in advanced melanoma [J]. N Engl J Med, 2015, 372: 2521-2532.
[27]Blidner AG, Mario KV, Rabinovich GA. Driving CARs into Sweet Roads: Targeting Glycosylated Antigens in Cancer [J]. Immunity, 2016, 44: 1248-1250.
[28]posey AD Jr. Schwab RD, Boesteanu AC, et al. Engineered CAR T Cells Targeting the cancer-associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma[J]. Immunity, 2016, 44: 1444-1454.
[29]Spear P, Barber A, Rynda-Apple A,et al. NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors [J]. Immunol Cell Biol, 2013, 91: 435-440.
[30]Hollie J, Rafiq S, Brentjens RJ. Driving CAR T-cells forward [J]. Nat Rev Clin Oncol, 2016, 13: 370-383.
[31]Brown CE, Alizadeh D, Starr R, et al. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy [J]. New Engl J Medi, 2016, 375: 2561-2569.
[32]Tang Q, Henriksen KJ, Bi M, et al.In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes [J]. J Exp Med, 2004, 199: 1455-1465.
[33]Brunstein CG, Miller JS, Cao Q, et al.Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics [J]. Blood, 2011, 117: 1061-1070.
[34]Jethwa H, Adami AA, Maher J. Use of gene-modified regulatory T-cells to control autoimmune and alloimmune pathology: Is now the right time?[J] Clin Immunol, 2013, 150: 51-63.
[35]Eleebrecht CT, Bhoj VG, Nace A, et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease[J]. Science, 2016, 353: 179-84.
[36]Hutter G, Nowak D, Mossner M, et al. Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation[J]. New Engl J Med, 2009, 360: 692-696.
[37]Rossi JJ, June CH, Kohn DB.Genetic Therapies for HIV/AIDS [J]. Nat Biotechnol, 2007, 25: 1444-1454.
[38]Deng K, Pertea M, Rongvaux A, et al.Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations [J]. Nature, 2015, 517: 381-385.
[39]Ali A, Kitchen SG, Chen IS, et al. HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies[J]. J Virol, 2016, 90: 6999-7006

相似文献/References:

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2017-01-20